Kate Bailey, PhD, is a Content Marketing Manager for Clinical Genomics at QIAGEN. Having completed her PhD in molecular microbiology and biochemistry at the University of Oxford, she went on to research host-pathogen interactions in plant and human systems. Passionate about communicating science, Kate has been working in the journal editing, medical writing and scientific marketing communications sectors since 2013.
Recent statistics have placed lung cancers as the second most common form of cancer and by far the leading cause of cancer death in both men and women (1). With poor survival rates using current treatments, gaining a better understanding of the underlying molecular drivers of lung cancers has been the focus of numerous research… Read article →
New improved chemistry for first Sample to Insight next-generation sequencing solution to be made available to first customers in December 2016 Charlotte, North Carolina, and Hilden, Germany, November 9, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the validation of new and improved sequencing chemistry for its GeneReader NGS System, the… Read article →
Join us at AMP for solutions, from trusted molecular detection to clinical decision support The AMP 2016 Annual Meeting is just around the corner, and we’re excited to see you there at the Convention Center in Charlotte, NC, Nov 10—12! Stop by our booth! Come to booth #1119 to explore our products and speak with our… Read article →
Hilden, Germany, and Germantown, Maryland, July 27, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new PAXgene® Blood ccfDNA Tube* for venous whole blood collection and room temperature stabilization of in-vivo circulating cell-free DNA (ccfDNA) profiles. Together with the QIAamp Circulating Nucleic Acid Kit – the gold… Read article →
QIAGEN partners with the Royal Oman Police to establish a national DNA database called Yaqeen.… https://t.co/UnO55tYxqX, QIAGEN reports results for second quarter and first half of 2018: https://t.co/RICyBelEtJ https://t.co/VwVZQuIrFd, QIAGEN partners with U.K. to expand biomarker research in Manchester
Read the full announcement:… https://t.co/tytlFQzoOf, QIAGEN’s QuantiFERON-TB® Gold Plus wins UN migration agency’s tender
Read the full announcement:… https://t.co/WOJPE5YCcc, We're pleased to announce that the artus CMV QS-RGQ MDx Kit (US) is a nominee for Best New Clinical Assay/Kit of 20… https://t.co/lMWFSWako1, 